Study on the Clinical Efficacy of Combined Therapy with Minocycline Hydrochloride Ointment and Tinidazole for Chronic Periodontitis: Retrospective Study.

Abstract

Objective: To analyze the clinical efficacy of combined minocycline hydrochloride and tinidazole therapy for chronic periodontitis (CP).

Methods: A retrospective analysis was conducted on clinical data from 93 CP patients admitted to our hospital from January 2021 to January 2023. All patients met the inclusion and exclusion criteria. They were divided into a control group (n=46) and an observation group (n=47). All patients received full-mouth ultrasonic debridement. On this basis, patients in the control group received weekly subgingival minocycline hydrochloride ointment (Sunstar^®) injections, while patients in the observation group received combined 500 mg tinidazole tablets twice daily ×4 weeks. Periodontal parameters and gingival crevicular fluid (GCF) biomarkers were assessed at baseline and 3-month follow-up.

Results: The results showed that the total effective rate of treatment in the observation group (91.49%) was significantly higher than that in the control group (73.91%) (P<0.05). The periodontal indicators (Plaque Index, Gingival Bleeding Index, Periodontal Pocket Depth), inflammatory factor indicators (C-reactive protein, Tumor Necrosis Factor-α, Interleukin-1β), Matrix Metalloproteinase-9 (MMP-9), and Secretory Immunoglobulin A (SIgA) levels of both groups decreased significantly after treatment. Moreover, these indicators in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

Conclusion: The combination therapy of minocycline hydrochloride and tinidazole significantly improved the clinical efficacy for CP patients. Compared with minocycline hydrochloride alone, the addition of tinidazole further improved patients' periodontal health, reduced the inflammatory response and MMP-9, SIgA levels, and did not increase the risk of adverse reactions. This suggests good drug safety and clinical promotion value.